Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3JT
|
|||
| Former ID |
DIB006343
|
|||
| Drug Name |
Cantuzumab mertansine
|
|||
| Synonyms |
Cantuzumab ravtansine; Cantuzumab ravtansine); HuC242-DM1; HuC242-DM4; IMGN-242; L-DM4; Modified cantuzumab mertansine, ImmunoGen; SB-408075; SB-40875; Ansamitocin-anticolon Ab conjugate, ImmunoGen/GlaxoSmithKline; Ansamitocin-anticolon Ab conjugate, ImmunoGen/SmithKline Beecham; DM1-anticolon Ab conjugate, ImmunoGen/GSK; DM1-anticolon Ab conjugate, ImmunoGen/GlaxoSmithKline; DM1-anticolon Ab conjugate, ImmunoGen/SmithKline Beecham
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Company |
ImmunoGen Inc; ImmunoGen
|
|||
| Structure |
 |
Download2D MOL |
||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00620607) huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.